CTDSPL2

Across TCGA pan-cancer cohorts, CTDSPL2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CTDSPL2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CTDSPL2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CTDSPL2 is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where CTDSPL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CTDSPL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.311	<.001	11	view →
LSCC	Male	II,III,IV	+0.487	<.001	8	view →
HNSC	Male	IV	+0.481	<.001	8	view →
PDAC	All	All	−0.200	.002	7	view →
COAD	All	All	+0.160	.001	6	view →
LUAD	Female	II,III,IV	−0.209	.002	2	view →
LUAD	Male	All	+0.133	.002	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 6 lineages.

CTDSPL2–CCRCC

Open the CCRCC breakdown →